PCH
MLTX icon

Polar Capital Holdings’s MoonLake Immunotherapeutics MLTX Stock Holding History

Polar Capital Holdings’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-247,500
Closed -$11.7M – 278
2025
Q2 		$11.7M Sell
247,500
-852,500
-78% -$34.7M 0.06% 177
2025
Q1 		$43M Hold
1,100,000
– – 0.26% 106
2024
Q4 		$59.6M Buy
1,100,000
+600,000
+120% +$30.6M 0.33% 78
2024
Q3 		$25.2M Sell
500,000
-178,169
-26% -$8.35M 0.12% 122
2024
Q2 		$29.8M Sell
678,169
-179,788
-21% -$7.62M 0.18% 111
2024
Q1 		$43.1M Sell
857,957
-79,158
-8% -$4.29M 0.23% 95
2023
Q4 		$56.6M Sell
937,115
-1,897
-0.2% -$97.8K 0.35% 81
2023
Q3 		$53.5M Sell
939,012
-676,377
-42% -$37.3M 0.4% 73
2023
Q2 		$82.4M Buy
1,615,389
+739,012
+84% +$19.9M 0.42% 59
2023
Q1 		$18.7M Hold
876,377
– – 0.12% 143
2022
Q4 		$9.2M Buy
+876,377
New +$7.79M 0.07% 198

Other funds holding MLTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Polar Capital Holdings's MLTX Position: Q3 2025 in Review

Polar Capital Holdings sold out of MoonLake Immunotherapeutics (MLTX) in Q3 2025, closing a stake of 247,500 shares — an estimated $11.7M sold.

Polar Capital Holdings first reported a position in MLTX in Q4 2022 and held it in 11 quarters. The position peaked at $82.4M in Q2 2023. 134 funds tracked by Wall St. Rank hold MLTX as of Q3 2025.

  • Polar Capital Holdings reported no remaining MoonLake Immunotherapeutics position as of Q3 2025 after selling out during the quarter.
  • Polar Capital Holdings sold 247,500 MoonLake Immunotherapeutics shares in Q3 2025, an estimated $11.7M.
  • Polar Capital Holdings first reported a position in MoonLake Immunotherapeutics in Q4 2022 and held it in 11 quarters.
  • Polar Capital Holdings's MoonLake Immunotherapeutics position peaked at $82.4M in Q2 2023.
  • 134 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q3 2025.

Based on Polar Capital Holdings's 13F filing for Q3 2025, filed 14 Nov 2025.